tetano
Editor, Senior Moderator
Vaccine. 2015 Mar 25. pii: S0264-410X(15)00340-0. doi: 10.1016/j.vaccine.2015.03.041. [Epub ahead of print]
[h=1]A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy.[/h] Fabiani M[SUP]1[/SUP], Bella A[SUP]1[/SUP], Rota MC[SUP]1[/SUP], Clagnan E[SUP]2[/SUP], Gallo T[SUP]3[/SUP], D'Amato M[SUP]4[/SUP], Pezzotti P[SUP]4[/SUP], Ferrara L[SUP]5[/SUP], Demicheli V[SUP]5[/SUP], Martinelli D[SUP]6[/SUP], Prato R[SUP]6[/SUP], Rizzo C[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Although concerns about safety of influenza vaccination during pregnancy have been raised in the past, vaccination of pregnant women was recommended in many countries during the 2009 A/H1N1 pandemic influenza. A retrospective cohort study was conducted to evaluate the risk of adverse maternal, fetal and neonatal outcomes among pregnant women vaccinated with a MF59-adjuvanted A/H1N1 pandemic influenza vaccine. The study was carried out in four Italian regions (Piemonte, Friuli-Venezia-Giulia, Lazio, and Puglia) among 102,077 pregnant women potentially exposed during the second or third trimester of gestation to the vaccination campaign implemented in 2009/2010. Based on data retrieved from the regional administrative databases, the statistical analysis was performed using the Cox proportional-hazards model, adjusting for the propensity score to account for the potential confounding effect due to the socio-demographic characteristics and the clinical and reproductive history of women. A total of 100,332 pregnant women were eligible for the analysis. Of these, 2003 (2.0%) received the A/H1N1 pandemic influenza vaccination during the second or third trimester of gestation. We did not observe any statistically significant association between the A/H1N1 pandemic influenza vaccination and different maternal outcomes (hospital admissions for influenza, pneumonia, hypertension, eclampsia, diabetes, thyroid disease, and anaemia), fetal outcomes (fetal death after the 22nd gestational week) and neonatal outcomes (pre-term birth, low birth weight, low 5-min Apgar score, and congenital malformations). Pre-existing health-risk conditions (hospital admissions and drug prescriptions for specific diseases before the onset of pregnancy) were observed more frequently among vaccinated women, thus suggesting that concomitant chronic conditions increased vaccination uptake. The results of this study add some evidence on the safety of A/H1N1 pandemic influenza vaccination during pregnancy but, because of the reduced statistical power, meta-analyses and large multi-centres studies are needed in order to obtain more conclusive results, especially for rare outcomes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] A/H1N1pdm09; Influenza; Pandemic vaccination; Pregnancy; Pregnancy outcomes; Safety
PMID: 25820060 [PubMed - as supplied by publisher]
[h=1]A/H1N1 pandemic influenza vaccination: A retrospective evaluation of adverse maternal, fetal and neonatal outcomes in a cohort of pregnant women in Italy.[/h] Fabiani M[SUP]1[/SUP], Bella A[SUP]1[/SUP], Rota MC[SUP]1[/SUP], Clagnan E[SUP]2[/SUP], Gallo T[SUP]3[/SUP], D'Amato M[SUP]4[/SUP], Pezzotti P[SUP]4[/SUP], Ferrara L[SUP]5[/SUP], Demicheli V[SUP]5[/SUP], Martinelli D[SUP]6[/SUP], Prato R[SUP]6[/SUP], Rizzo C[SUP]7[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Although concerns about safety of influenza vaccination during pregnancy have been raised in the past, vaccination of pregnant women was recommended in many countries during the 2009 A/H1N1 pandemic influenza. A retrospective cohort study was conducted to evaluate the risk of adverse maternal, fetal and neonatal outcomes among pregnant women vaccinated with a MF59-adjuvanted A/H1N1 pandemic influenza vaccine. The study was carried out in four Italian regions (Piemonte, Friuli-Venezia-Giulia, Lazio, and Puglia) among 102,077 pregnant women potentially exposed during the second or third trimester of gestation to the vaccination campaign implemented in 2009/2010. Based on data retrieved from the regional administrative databases, the statistical analysis was performed using the Cox proportional-hazards model, adjusting for the propensity score to account for the potential confounding effect due to the socio-demographic characteristics and the clinical and reproductive history of women. A total of 100,332 pregnant women were eligible for the analysis. Of these, 2003 (2.0%) received the A/H1N1 pandemic influenza vaccination during the second or third trimester of gestation. We did not observe any statistically significant association between the A/H1N1 pandemic influenza vaccination and different maternal outcomes (hospital admissions for influenza, pneumonia, hypertension, eclampsia, diabetes, thyroid disease, and anaemia), fetal outcomes (fetal death after the 22nd gestational week) and neonatal outcomes (pre-term birth, low birth weight, low 5-min Apgar score, and congenital malformations). Pre-existing health-risk conditions (hospital admissions and drug prescriptions for specific diseases before the onset of pregnancy) were observed more frequently among vaccinated women, thus suggesting that concomitant chronic conditions increased vaccination uptake. The results of this study add some evidence on the safety of A/H1N1 pandemic influenza vaccination during pregnancy but, because of the reduced statistical power, meta-analyses and large multi-centres studies are needed in order to obtain more conclusive results, especially for rare outcomes.
Copyright ? 2015. Published by Elsevier Ltd.
[h=4]KEYWORDS:[/h] A/H1N1pdm09; Influenza; Pandemic vaccination; Pregnancy; Pregnancy outcomes; Safety
PMID: 25820060 [PubMed - as supplied by publisher]